Supplementary Data from Treatment Strategies and Mechanisms Associated with the Prevention of NASH-Associated HCC by a Toll-like Receptor 4 Inhibitor
Suet‐Ying Kwan(The University of Texas MD Anderson Cancer Center), Laura Beretta(The University of Texas MD Anderson Cancer Center), Michelle I. Savage(The University of Texas MD Anderson Cancer Center), Huiqin Chen(The University of Texas MD Anderson Cancer Center), Mihai Gagea(The University of Texas MD Anderson Cancer Center), Shizuko Sei(National Cancer Institute), Rosamaria C. Marquez(The University of Texas MD Anderson Cancer Center), Alyssa N. Slayden(The University of Texas MD Anderson Cancer Center), Gregory K. Wilkerson(The University of Texas MD Anderson Cancer Center), Powel H. Brown(The University of Texas MD Anderson Cancer Center), Jennifer T. Fox(National Cancer Institute), Aubrey R. Coronado(The University of Texas MD Anderson Cancer Center), Lana A. Vornik(Unknown), Dong Liang(Tongji University), Heather L. Stevenson(The University of Texas Medical Branch at Galveston), Peng Wei(Creighton University)
Cited by 0
Related Papers
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
|Genome biology|2007|1.3k
Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies
|Human Molecular Genetics|2014|1.2k
Estimates of benefits and harms of prophylactic use of aspirin in the general population
|Annals of Oncology|2014|388
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
|The Lancet. Gastroenterology & hepatology|2022|255